Gini Fleming, MD
Professor of Medicine, Section of Hematology and Oncology
Medical Director, Gynecologic Oncology
University of Chicago Medicine
Dr. Fleming is an expert in breast and gynecological cancers. She has served as principal investigator or investigator on numerous phase I, II, and III clinical trials and has authored or co-authored more than 150 articles in top peer-reviewed journals including the New England Journal of Medicine, Lancet Oncology, Clinical Cancer Research, the Journal of Clinical Oncology and others, in addition to a number of textbook chapters. She serves on the editorial board for Gynecologic Oncology. She earned her MD from the University of Illinois College of Medicine and completed internship, residency, and fellowship training at the University of Chicago Medicine.
V. Craig Jordan, CMG, OBE, PhD, DSc, FMedSci
Dallas/Fort Worth Living Legend Chair of Cancer Research
Professor of Breast Medical Oncology and Molecular and Cellular Oncology
Chief, Section of Basic Science Research and Pharmacology
University of Texas MD Anderson Cancer Center
Member of the National Academy of Sciences, National Academy of Medicine
Dr. Jordan’s translational research over the past four decades established the standard of care for the endocrine treatment of breast cancer, chemoprevention of breast cancer and the first studies of the evolution of drug resistance to long-term anti-estrogen therapy. Dr. Jordan’s findings include application of the original SERM, the estrogen-blocking drug tamoxifen, to the treatment and prevention of breast cancer, and discovery that raloxifene prevents both osteoporosis and breast cancer. The two widely used drugs are among five SERMs approved by the FDA for a variety of indications and all five are connected to basic research in Dr. Jordan’s laboratory.
Ruth M. O’Regan, MBBCh, BAO
Charles A. Dewey Professor and Chair of Medicine
University of Rochester School of Medicine and Dentistry
Physician-in-Chief Strong Memorial Hospital
Associate Director of Education and Mentoring at the Wilmot Cancer Institute
Dr. O’Regan specializes in the study of mechanisms of resistance to therapy in breast cancer and on the development of novel treatments for triple-negative breast cancer. Prior to joining the University of Rochester in 2020, she was the Chief of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health and the Deputy Director of the Carbone Cancer Center. She was the Chief Scientific Officer of the Big Ten Cancer Research Consortium, a collaborative program leveraging the scientific and clinical expertise at the Big Ten universities to advance translational oncology research. She was also vice-chair of the National Comprehensive Cancer Network Board of Directors.
Douglas Yee, MD
Professor of Medicine and Pharmacology (Joint Appointment), Division of Hematology, Oncology and Transplantation
Director, Masonic Cancer Center
University of Minnesota Medical School
Dr. Yee is a medical oncologist specializing in breast cancer; his research program investigates the role of insulin and insulin-like growth factors in the regulation of cancer cells. He holds the distinction of being the John H. Kersey Chair in Cancer Research since 2008 and has been the director of the Masonic Cancer Center since 2007. Dr Yee earned his MD in 1981 from the University of Chicago. He received his internal medicine training and was chief resident at the University of North Carolina. He pursued a medical oncology fellowship at the National Cancer Institute in Bethesda, Maryland. He held faculty positions at Georgetown University Medical Center and the University of Texas Health Science Center at San Antonio.